Atrial fibrillation epidemiologic, economic and individual burden of disease;Vorhofflimmern - epidemiologische, ökonomische und individuelle Krankheitsbelastung

Deutsche Medizinische Wochenschrift

Volumn 135, Issue SUPPL. 2, 2010, Pages

  Bruggenjurgen B ^a   Reinhold, T ^b   McBride, D ^b   Willich, S N ^b  

^a STEINBEIS UNIVERSITY BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atrial fibrillation; Health care; Quality of life

Indexed keywords

CLINICAL FEATURE; ECONOMIC ASPECT; HEART ATRIUM FIBRILLATION; HUMAN; PREVALENCE; REVIEW; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; POPULATION DYNAMICS; QUALITY OF LIFE; STROKE;

EID: 77949388526     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1249204     Document Type: Review

References (51)

1. Benjamin E J., Levy D, Vaziri S M. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 271 840-844
2. Bialy D, Lehmann M H., Schumacher D N. et al. Hospitalization for arrythmias in the United States; importance of atrial fibrillation. J Am Coll Cardiol 1992 19 41A
3. Bilato C, Corti M C., Baggio G et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). Am J Cardiol 2009 104 1092-1097
4. Bruggenjurgen B, Rossnagel K, Roll S et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health 2007 10 137-143
5. Busse R, Drösler S, Glaeske G et al. Wissenschaftliches Gutachten für die Auswahl von 50 bis 80 Krankheiten zur Berücksichtigung im morbiditätsorientierten Risikostrukturausgleich. http://www.der- gesundheitsfonds.de/fileadmin/redaktion/Dokumente/Gutachten-Beirat- Krankheitsauswahl-gesamt.pdf Dezember 2007. Letzter Zugriff 3.3.2010
6. Crandall M A., Horne B D., Day J D. et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol 2009 32 981-986
7. Friberg J, Scharling H, Gadsboll N, Jensen G B. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol 2003 92 1419-1423
8. Fuster V, Ryden L E., Asinger R W. et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001 38 1231-1266
9. Gehring J, Perz S, Stieber J et al. Cardiovascular risk factors, ECG abnormalities and quality of life in subjects with atrial fibrillation. Soz Praventivmed 1996 41 185-193
10. Gillis A M., Rose M S. Temporal patterns of paroxysmal atrial fibrillation following DDDR pacemaker implantation. Am J Cardiol 2000 85 1445-1450
11. Go A S., Hylek E M., Phillips K A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001 285 2370-2375
12. Go A S. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol 2005 14 56-61
13. Hart R G., Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 131 492-501
14. Hathaway W E., Goodnight S H. In: Disorder of hemostatis and thrombosis: A clinical guide. 2nd ed. New York McGraw Hill 2001 560
15. Heeringa J, van der Kuip D A., Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006 27 949-953
16. Howard P A. Guidelines for stroke prevention in patients with atrial fibrillation. Drugs 1999 58 997-1009
17. Howes C J., Reid M C., Brandt C et al. Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation. J Cardiovasc Pharmacol Ther 2001 6 23-29
18. Janko S, Hoffmann E, Schimmel S et al. Prävalenz von Vorhofflimmern in der Allgemeinbevölkerung: das KORA-AF-EVENT-Projekt. Z Kardiol 2004 93 P783
19. Körfer R, Horstkotte D, Spannagl M, Völler H. Orale Langzeitantikoagulation Wenn Patienten sich selber testen und einstellen. Dtsch rztebl 2004 101 A549
20. Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001 32 392-398
21. Lin H J., Wolf P A., Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996 27 1760-1764
22. Mattle H P., Schwerzmann M, Seiler C. Vorhofflimmern und Hirninfarkt. Ther Umsch 2003 60 527-534
23. McBride D, Bruggenjurgen B, Roll S, Willich S N. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis 2007 24 65-72
24. McBride D, Mattenklotz A M., Willich S N., Bruggenjurgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 2008 12 293-301
25. Miller P S., Andersson F L., Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 2005 36 360-366
26. Miller P SJ, Drummond M, Langkilde L et al. Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. Eur Heart J 2005 7 C41-C54
27. MSD-Manual der Diagnostik und Therapie. 5. Auflage ed München, Wien, Baltimore Urban & Schwarzenberg 1993
28. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009 11 423-434
29. Reinhold T, Hessel F, Willich S N., Brüggenjürgen B. Kostenverlauf nach Vorhofflimmern bei Patienten mit kardialer Komorbidität. 2. Jahreskonferenz der Deutschen Gesellschaft für Gesundheitsökonomie (dggö). 1. und 2. März 2010,. Berlin 2010 Letzter Zugriff 10.2.2010
30. Reynolds M W., Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004 126 1938-1945
31. Ruigomez A, Johansson S, Wallander M A., Rodriguez L A. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002 55 358-363
32. Rychlik R. Gesundheitsökonomie Grundlagen und Praxis. Stuttgart Enke 1999 15-172
33. Sack S. Epidemiologie des Vorhofflimmerns. Herz 2002 27 294-300
34. Sanoski C A. Clinical, economic, and quality of life impact of atrial fibrillation. J Manag Care Pharm 2009 15 S4-S9
35. Savelieva I, Bajpai A, Camm A J. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007 39 371-391
36. Savelieva I, Paquette M, Dorian P et al. Quality of life in patients with silent atrial fibrillation. Heart 2001 85 216-217
37. Schuchert A, Gulba D, Horstkotte, DH et al. Kommetar zu den ACC/AHA/ESC-Leitlinien 2001 zur Prävention arterieller Thromboembolien bei Patienten mit Vorhofflimmern. Z Kardiol 2003 92 694-703
38. Scottish Intercolleciate Guidelines Network (SIGN). Antithrombotic Therapy http://www.sign.ac.uk/pdf/sign36.pdf 1999 Letzter Zugriff am 3.3.2010
39. Statistisches Bundesamt Wiesbaden. A 1 Bevölkerung am 31.12.2004 nach Alters- und Geburtsjahren. http://www.destatis.de (auf Anfrage) 2002 208-2004
40. Stewart S, Murphy N, Walker A et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004 90 286-292
41. Thrall G, Lane D, Carroll D, Lip G Y. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006 119 448-419
42. van der Meer F J., Rosendaal F R., Vandenbroucke J P., Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996 76 12-16
43. WC, Hart R G., Singer D E. et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002 20;288 2441-2448
44. Wang T J., Massaro J M., Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003 290 1049-1056
45. Warman E N., Grammatico A, Padeletti L. Sample size estimates for atrial fibrillation endpoints. Heart Rhythm 2004 1 B58-62, discussion
46. Willich S N. Vorhofflimmern: Epidemiologie und Kosten. 51. Deutscher rztekongress. Berlin 2002 166-2002
47. Wolf P A., Abbott R D., Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 22 983-988
48. Wolf P A., Mitchell J B., Baker C S., Kannel W B., DAgostino R B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998 158 229-234
49. World Heart Federation. Cardiology Groups Call For Greater Awareness And Better Education On Atrial Fibrillation. World Heart Federation 82-2010, 102-2010
50. Yoneda Y, Uehara T, Yamasaki H et al. Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke 2003 34 718-724
51. Reinhold T, Kohlhaussen A, Bonnemeier H, Bosch R F., Willich S N., Kirch W. Kosten von Vorhofflimmern in Deutschland: BaselineErhebung des MOVERegisters. 2. Jahreskonferenz der Deutschen Gesellschaft für Gesundheitsökonomie (dggö) 1. und 2. März 2010, Berlin